Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial
Authors' conclusion
GLP-1RAs reduced MACE risk similarly across eGFR strata, while lower eGFR was associated with a larger estimated absolute cardiovascular benefit.
Study context
- Population
- Adults with T2D or overweight/obesity in randomized placebo-controlled GLP-1 RA trials reporting estimated glomerular filtration rate (eGFR)-stratified major adverse cardiovascular events (MACE)
- Participants
- 70,822 adults8 trials
- Comparison
- GLP-1 RA vs placebo, by baseline eGFR
- Outcome
- MACE by baseline eGFR stratum
Methodological detailsrandom-effects, placebo-controlled trials, PubMed and EMBASE searched to 29 April 2026, 9 publications from 8 trials
- Random-effects
- Placebo-controlled trials
- PubMed and EMBASE searched to 29 April 2026
- 9 publications from 8 trials
Pooled result
As reported in the abstract
MACE
MACE eGFR < 60 pooled HR 0.83 (95% CI 0.74–0.93) · eGFR ≥ 60 pooled HR 0.83 (95% CI 0.77–0.90)
p eGFR < 60 p < 0.001 · eGFR ≥ 60 p < 0.001
I2
- Pooled ratio of HRs (RHR) (eGFR < 60 vs ≥ 60 mL/min/1.73 m²): no evidence of effect modification
- 1.02, 95% CI 0.85-1.21; p = 0.84
Further pooled results
Exploratory ARR and NNT for MACE · exploratory
NNT eGFR < 60 39 (95% CI 26-91) · eGFR ≥ 60 62 (95% CI 46-101)
Original publication
Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial. Diabetes Obes Metab. Published 25 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →